EGFR was aberrantly activated in many cancers and was an important drug target for cancer therapies; however, almost all patients who initially benefited from EGFR-targeted therapies eventually developed resistance (Chong and Jänne, 2013; Guardiola et al, 2019; Sigismund et al, 2018). The gene discussed is EGFR; the disease is cancer.